妊娠滋养细胞肿瘤的免疫治疗  

Immunotherapy for gestational trophoblastic neoplasia.

作　　者：程红燕 向阳[1] CHENG Hong-yan;XIANG Yang(Department of Gynecology and Obstetrics,Peking Union Medical College Hospital,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100730,China)

机构地区：[1]中国医学科学院北京协和医学院北京协和医院妇产科,北京100730

出　　处：《中国实用妇科与产科杂志》2022年第7期693-696,共4页Chinese Journal of Practical Gynecology and Obstetrics

基　　金：国家自然科学基金(81971475,81972451)。

摘　　要：妊娠滋养细胞肿瘤(gestational trophoblastic neoplasia,GTN)是由妊娠继发的疾病,虽然对化疗高度敏感,但仍有部分患者因耐药、复发而死亡。由于疾病起源与免疫密切相关,免疫治疗在难治性GTN中的尝试初显成效。随着对新兴免疫靶点研究的不断深入,免疫治疗逐渐成为近年来GTN挽救治疗的研究热点,文章将重点讨论GTN的免疫治疗研究进展。Gestational trophoblastic neoplasia(GTN)is a subsequent disease to pregnancy.Although it is highly sensitive to chemotherapy,some patients still died of drug resistance and relapse.Since the disease origin is closely related to immunity,immunotherapy has shown initial success in refractory GTN.With the deepening of the research on emerging immune targets,immunotherapy has gradually become the focus of GTN salvage therapy in recent years.This review will focus on the research progress about immunotherapy for GTN.

关 键 词：妊娠滋养细胞肿瘤 免疫治疗 程序性死亡蛋白1 

分 类 号：R737.33[医药卫生—肿瘤]